| Multiple Sclerosis, Secondary Progressive
Copaxone vs Rebif
Side-by-side clinical, coverage, and cost comparison for multiple sclerosis, secondary progressive.Deep comparison between: Copaxone vs Rebif with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRebif has a higher rate of injection site reactions vs Copaxone based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rebif but not Copaxone, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Copaxone
Rebif
At A Glance
SC injection
Daily or 3x weekly
Immunomodulator
SC injection
Three times per week
Interferon beta-1a
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
Dosing
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive 20 mg/mL SC once daily OR 40 mg/mL SC three times per week (at least 48 hours apart); the two strengths are not interchangeable.
Clinically isolated syndrome, Multiple Sclerosis Relapsing-Remitting, Multiple Sclerosis Secondary Progressive 22 mcg or 44 mcg SC three times per week; titrate starting at 20% of prescribed dose over a 4-week period to the targeted dose; administer at the same time on the same three days at least 48 hours apart each week.
Contraindications
- Known hypersensitivity to glatiramer acetate or mannitol, including anaphylaxis
- History of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation
Adverse Reactions
Most common (>=2%) Injection site erythema, pain, pruritus, mass, edema, and inflammation; vasodilatation, rash, dyspnea, chest pain, nausea, palpitations, lymphadenopathy, asthenia, anxiety, infection
Serious Anaphylactic reactions, immediate post-injection reaction, chest pain, lipoatrophy and skin necrosis, potential effects on immune response, hepatic injury
Postmarketing Sepsis, SLE syndrome, thrombosis, myocardial infarct, thrombocytopenia, lymphoma-like reaction, acute leukemia, cirrhosis, hepatic injury, anaphylactic reactions, cerebrovascular accident, pulmonary embolus, blindness
Most common Injection site reaction, influenza-like symptoms, headache, fatigue, fever, leukopenia, elevated liver enzymes (SGPT, SGOT), myalgia, back pain, abdominal pain, depression
Serious Depression and suicide, hepatic injury, anaphylaxis and other allergic reactions, injection site necrosis, decreased peripheral blood counts, thrombotic microangiopathy, pulmonary arterial hypertension, seizures
Postmarketing Drug-induced lupus erythematosus, autoimmune hepatitis, retinal vascular disorders, pulmonary arterial hypertension, erythema multiforme, Stevens-Johnson syndrome, hemolytic anemia
Pharmacology
Glatiramer acetate is an immunomodulator thought to act by modifying immune processes responsible for MS pathogenesis; upon SC administration, glatiramer acetate-specific suppressor T-cells are induced and activated in the periphery.
Interferon beta-1a; the exact mechanism(s) by which REBIF exerts its therapeutic effects in multiple sclerosis is unknown, but it is a recombinant form of human interferon beta produced in Chinese Hamster Ovary cells with an amino acid sequence identical to natural fibroblast-derived human interferon beta.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Copaxone
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (1/12) · Qty limit (11/12)
Rebif
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Copaxone
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (7/8)
Rebif
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (0/8)
Humana
Copaxone
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Rebif
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CopaxoneView full Copaxone profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.